This volume examines the impact of recent executive actions on federal health communication, along with concerns and stigmas surrounding ADHD diagnoses and treatments, including skepticism about pharmaceutical influence on medication promotion. It also explores distrust in food regulations following the FDA’s ban on Red Dye No. 3.
With all the roadblocks providers are facing to better patient access, where do they start? Here are some ways to solve some of the biggest challenges hindering a streamlined workflow. The post Progress and Gaps: Fixing the Barriers to Patient Access appeared first on MedCity News.
Health and Human Services Secretary Robert F. Kennedy Jr.’s testimony before the Senate Finance Committee follows the ouster last week of the director of the Centers for Disease Control and Prevention, Susan Monarez. At least four other senior CDC officials resigned in protest. What are the biggest takeaways? What comes next? Tune in for a…
From CMS yesterday: On January 27, 2026, CMS announced the selection of the below list of 15 drugs payable under Medicare Part B and/or covered under Medicare Part D for the third cycle of negotiations (initial price applicability year 2028), based on total expenditures for drugs payable under Part B and/or covered under Part D…
President Donald Trump’s return to the White House sent a clear signal about Medicaid to Republicans across the country: Requiring enrollees to prove they are working, volunteering, or going to school is back on the table. The day after Trump’s inauguration, South Carolina GOP Gov. Henry McMaster asked federal officials to approve a work requirement…
Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but the drug’s mixed record in clinical testing warrants exploration about the reasons for failure, which could identify the appropriate patients for the eye drop. AbbVie holds an option to collaborate on commercialization of reproxalap. The post ‘Lack…
Acadia Pharmaceuticals did not disclose the buyer of the priority review voucher. The biotech received the voucher last year alongside the regulatory decision that made its drug Daybue the first FDA-approved treatment for the rare disease Rett syndrome. The post Acadia Pharma Sells Voucher for Speedier FDA Drug Review for $150M appeared first on MedCity…
This volume explores confusion around COVID-19 booster eligibility as federal recommendations shift and conflicts with guidance from physician organizations; Florida’s decision to end school vaccine mandates; and research demonstrating that artificial intelligence chatbots can provide generally sound advice, but struggle to make personalized recommendations.
Hospitals’ costs are climbing steadily — driven by chronic underpayments from payers, growing administrative requirements and increasing labor costs, according to a new report from the American Hospital Association. The post Hospitals’ Costs Are Soaring: 3 Stats to Know appeared first on MedCity News.